


REMARKS

Applicants have canceled claims 102-107 and amended claims 101 and 113. Claims 101 and 108-113 are currently pending. Reconsideration of the application is respectfully requested. In particular, amended claim 101 requires that the resin include a carbonyl containing moiety and that the step of attaching the plurality of aryl oxazolidinones to the plurality of solid supports in step (a) includes converting Q₂ to an iminophosphorane or an amine and reacting the iminophosphorane or the amine with the carbonyl moiety of the resin to form an imine. Thus, amended claim 101 specifically defines how and where the aryl oxazolidinones attach to the plurality of solid support resins. Claim 113 has been amended to correct the problem with antecedent basis. Regarding the issue of double patenting, Applicants submit herewith a terminal disclaimer to U.S. Patent No. 6,441,005.

Applicants submit that this application is now in condition for allowance, which action is respectfully requested.

Respectfully submitted,


Jonathan P. O'Brien, Patent Agent
Registration No. 50,852

Date: 1/22/04

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (269) 833-2102 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316